<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36341327</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Low perforin expression in CD8+ T lymphocytes during the acute phase of severe SARS-CoV-2 infection predicts long COVID.</ArticleTitle><Pagination><StartPage>1029006</StartPage><MedlinePgn>1029006</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1029006</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.1029006</ELocationID><Abstract><AbstractText>T cell cytotoxicity plays a major role in antiviral immunity. Anti-SARS-CoV-2 immunity may determine acute disease severity, but also the potential persistence of symptoms (long COVID). We therefore measured the expression of perforin, a cytotoxic mediator, in T cells of patients recently hospitalized for SARS-CoV-2 infection. We recruited 54 volunteers confirmed as being SARS-CoV-2-infected by RT-PCR and admitted to Intensive Care Units (ICUs) or non-ICU, and 29 age- and sex-matched healthy controls (HCs). Amounts of intracellular perforin and granzyme-B, as well as cell surface expression of the degranulation marker CD107A were determined by flow cytometry. The levels of 15 cytokines in plasma were measured by Luminex. The frequency of perforin-positive T4 cells and T8 cells was higher in patients than in HCs (9.9 &#xb1; 10.1% versus 4.6 &#xb1; 6.4%, p = 0.006 and 46.7 &#xb1; 20.6% vs 33.3 &#xb1; 18.8%, p = 0.004, respectively). Perforin expression was neither correlated with clinical and biological markers of disease severity nor predictive of death. By contrast, the percentage of perforin-positive T8 cells in the acute phase of the disease predicted the onset of long COVID one year later. A low T8 cytotoxicity in the first days of SARS-CoV-2 infection might favor virus replication and persistence, autoimmunity, and/or reactivation of other viruses such as Epstein-Barr virus or cytomegalovirus, paving the way for long COVID. Under this hypothesis, boosting T cell cytotoxicity during the acute phase of the infection could prevent delayed sequelae.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Kundura, Cezar, Andr&#xe9;, Campos-Mora, Lozano, Vincent, Muller, Lefrant, Roger, Claret, Duvnjak, Loubet, Sotto, Tran, Estaquier and Corbeau.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kundura</LastName><ForeName>Lucy</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Human Genetics, Unit&#xe9; Mixte de Recherche 9002 (UMR9002), Centre National de Recherche Scientifique (CNRS) and Montpellier University, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cezar</LastName><ForeName>Renaud</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Immunology Department, N&#xee;mes University Hospital, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andr&#xe9;</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM) U1124, Universit&#xe9; Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campos-Mora</LastName><ForeName>Mauricio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Regenerative Medicine &amp;amp; Biotherapy, Montpellier University Hospital, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lozano</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Immunology Department, Montpellier University Hospital, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vincent</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Immunology Department, Montpellier University Hospital, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muller</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Department, N&#xee;mes University Hospital, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lefrant</LastName><ForeName>Jean-Yves</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Department, N&#xee;mes University Hospital, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roger</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Department, N&#xee;mes University Hospital, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Claret</LastName><ForeName>Pierre-G&#xe9;raud</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Medical and Surgical Emergency Department, N&#xee;mes University Hospital, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duvnjak</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Gerontology Department, N&#xee;mes University Hospital, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loubet</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Infectious diseases Department, N&#xee;mes University Hospital, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sotto</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Infectious diseases Department, N&#xee;mes University Hospital, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Tu-Ahn</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Pediatrics Department, N&#xee;mes University Hospital, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estaquier</LastName><ForeName>J&#xe9;r&#xf4;me</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM) U1124, Universit&#xe9; Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Qu&#xe9;bec University Hospital, CHU de Qu&#xe9;bec, Laval University Research Center, Quebec City, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corbeau</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Human Genetics, Unit&#xe9; Mixte de Recherche 9002 (UMR9002), Centre National de Recherche Scientifique (CNRS) and Montpellier University, Montpellier, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Immunology Department, N&#xee;mes University Hospital, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>126465-35-8</RegistryNumber><NameOfSubstance UI="D054353">Perforin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054353" MajorTopicYN="N">Perforin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020031" MajorTopicYN="Y">Epstein-Barr Virus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">T lymphocytes</Keyword><Keyword MajorTopicYN="N">cytotoxicity</Keyword><Keyword MajorTopicYN="N">perforin</Keyword><Keyword MajorTopicYN="N">sequelae</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>7</Day><Hour>5</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36341327</ArticleId><ArticleId IdType="pmc">PMC9630742</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.1029006</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. . Clinical features of patients infected with 2019 novel coronavirus in wuhan, China. Lancet (2020) 395(10223):497&#x2013;506. doi: 10.1016/S0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. . Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science (2020) 369(6504): 718&#x2013;24. doi: 10.1101/2020.04.19.20068015</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.19.20068015</ArticleId><ArticleId IdType="pmc">PMC7402632</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId></ArticleIdList></Reference><Reference><Citation>Andre S, Picard M, Cezar R, Roux-Dalvai F, Alleaume-Butaux A, Soundaramourty C, et al. . T Cell apoptosis characterizes severe covid-19 disease. Cell Death Differ (2022) 29(8):1486&#x2013;99. doi: 10.1038/s41418-022-00936-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-022-00936-x</ArticleId><ArticleId IdType="pmc">PMC8782710</ArticleId><ArticleId IdType="pubmed">35066575</ArticleId></ArticleIdList></Reference><Reference><Citation>Kundura L, Gimenez S, Cezar R, Andre S, Younas M, Lin YL, et al. . Angiotensin II induces reactive oxygen species, DNA damage, and T cell apoptosis in severe COVID-19. J Allergy Clin Immunol (2022) 150(3):594&#x2013;603. doi: 10.1016/j.jaci.2022.06.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2022.06.020</ArticleId><ArticleId IdType="pmc">PMC9278992</ArticleId><ArticleId IdType="pubmed">35841981</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. . Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: A systematic review. JAMA Netw Open (2021) 4(10):e2128568. doi: 10.1001/jamanetworkopen.2021.28568</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F, Gemelli Against COVID-19 Post-Acute Care Study Group . Persistent symptoms in patients after acute COVID-19. JAMA (2020) 324(6):603&#x2013;5. doi: 10.1001/jama.2020.12603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1.</Citation></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. . Post-acute COVID-19 syndrome. Nat Med (2021) 27(4):601&#x2013;15. doi: 10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Sollini M, Ciccarelli M, Cecconi M, Aghemo A, Morelli P, Gelardi F, et al. . Vasculitis changes in COVID-19 survivors with persistent symptoms: An [(18)F]FDG-PET/CT study. Eur J Nucl Med Mol Imaging (2021) 48(5):1460&#x2013;6. doi: 10.1007/s00259-020-05084-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-020-05084-3</ArticleId><ArticleId IdType="pmc">PMC7595761</ArticleId><ArticleId IdType="pubmed">33123760</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye G, Pan Z, Pan Y, Deng Q, Chen L, Li J, et al. . Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation. J Infect (2020) 80(5):e14&#x2013;e7. doi: 10.1016/j.jinf.2020.03.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.001</ArticleId><ArticleId IdType="pmc">PMC7102560</ArticleId><ArticleId IdType="pubmed">32171867</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan RK, Kashour T, Hamid Q, Halwani R, Tleyjeh IM. Unraveling the mystery surrounding post-acute sequelae of COVID-19. Front Immunol (2021) 12:686029. doi: 10.3389/fimmu.2021.686029</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.686029</ArticleId><ArticleId IdType="pmc">PMC8278217</ArticleId><ArticleId IdType="pubmed">34276671</ArticleId></ArticleIdList></Reference><Reference><Citation>Tejerina F, Catalan P, Rodriguez-Grande C, Adan J, Rodriguez-Gonzalez C, Munoz P, et al. . Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19. BMC Infect Dis (2022) 22(1):211. doi: 10.1186/s12879-022-07153-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07153-4</ArticleId><ArticleId IdType="pmc">PMC8892394</ArticleId><ArticleId IdType="pubmed">35240997</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms. Front Microbiol (2021) 12:698169. doi: 10.3389/fmicb.2021.698169</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, et al. . Diverse functional autoantibodies in patients with COVID-19. Nature (2021) 595(7866):283&#x2013;8. doi: 10.1038/s41586-021-03631-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03631-y</ArticleId><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Marino Gammazza A, L&#xe9;gar&#xe9; S, Lo Bosco G, Fucarino A, Angileri F, Conway de Macario E, et al. . Human molecular chaperones share with SARS-CoV-2 antigenic epitopes potentially capable of eliciting autoimmunity against endothelial cells: possible role of molecular mimicry in COVID-19. Cell Stress Chaperones (2020) 25(5):737&#x2013;41. doi: 10.1007/s12192-020-01148-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12192-020-01148-3</ArticleId><ArticleId IdType="pmc">PMC7402394</ArticleId><ArticleId IdType="pubmed">32754823</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter AG, Shields AM, Karim A, Birch D, Faustini SE, Steadman L, et al. . Establishing the prevalence of common tissue-specific autoantibodies following severe acute respiratory syndrome coronavirus 2 infection. Clin Exp Immunol (2021) 205(2):99&#x2013;105. doi: 10.1111/cei.13623</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13623</ArticleId><ArticleId IdType="pmc">PMC8239842</ArticleId><ArticleId IdType="pubmed">34082475</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapkota HR, Nune A. Long COVID from rheumatology perspective - A narrative review. Clin Rheumatol (2022) 41(2):337&#x2013;48. doi: 10.1007/s10067-021-06001-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-021-06001-1</ArticleId><ArticleId IdType="pmc">PMC8629735</ArticleId><ArticleId IdType="pubmed">34845562</ArticleId></ArticleIdList></Reference><Reference><Citation>Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol (2020) 16(8):413&#x2013;4. doi: 10.1038/s41584-020-0448-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0448-7</ArticleId><ArticleId IdType="pmc">PMC7271827</ArticleId><ArticleId IdType="pubmed">32499548</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight JS, Caricchio R, Casanova JL, Combes AJ, Diamond B, Fox SE, et al. . The intersection of COVID-19 and autoimmunity. J Clin Invest (2021) 131(24): e154886. doi: 10.1172/JCI154886</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI154886</ArticleId><ArticleId IdType="pmc">PMC8670833</ArticleId><ArticleId IdType="pubmed">34710063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrenfeld M, Tincani A, Andreoli L, Cattalini M, Greenbaum A, Kanduc D, et al. . Covid-19 and autoimmunity. Autoimmun Rev (2020) 19(8):102597. doi: 10.1016/j.autrev.2020.102597</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102597</ArticleId><ArticleId IdType="pmc">PMC7289100</ArticleId><ArticleId IdType="pubmed">32535093</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens (2021) 10(6): 763. doi: 10.3390/pathogens10060763</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10060763</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. . Multiple early factors anticipate post-acute COVID-19 sequelae. Cell (2022) 185(5): 881&#x2013;95. doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt ME, Varga SM. The CD8 T cell response to respiratory virus infections. Front Immunol (2018) 9:678. doi: 10.3389/fimmu.2018.00678</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00678</ArticleId><ArticleId IdType="pmc">PMC5900024</ArticleId><ArticleId IdType="pubmed">29686673</ArticleId></ArticleIdList></Reference><Reference><Citation>Juno JA, van Bockel D, Kent SJ, Kelleher AD, Zaunders JJ, Munier CM. Cytotoxic CD4 T cells-friend or foe during viral infection? Front Immunol (2017) 8:19. doi: 10.3389/fimmu.2017.00019</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00019</ArticleId><ArticleId IdType="pmc">PMC5253382</ArticleId><ArticleId IdType="pubmed">28167943</ArticleId></ArticleIdList></Reference><Reference><Citation>Shustov A, Luzina I, Nguyen P, Papadimitriou JC, Handwerger B, Elkon KB, et al. . Role of perforin in controlling b-cell hyperactivity and humoral autoimmunity. J Clin Invest. (2000) 106(6):R39&#x2013;47. doi: 10.1172/JCI8876</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI8876</ArticleId><ArticleId IdType="pmc">PMC381389</ArticleId><ArticleId IdType="pubmed">10995792</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng SL, Moslehi J, Robert ME, Craft J. Perforin protects against autoimmunity in lupus-prone mice. J Immunol (1998) 160(2):652&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">9551899</ArticleId></ArticleIdList></Reference><Reference><Citation>Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, et al. . Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods (2003) 281(1-2):65&#x2013;78. doi: 10.1016/S0022-1759(03)00265-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-1759(03)00265-5</ArticleId><ArticleId IdType="pubmed">14580882</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan BE, Chong VCL, Chan SSW, Lim GH, Lim KGE, Tan GB, et al. . Hematologic parameters in patients with COVID-19 infection. Am J Hematol (2020) 95(6):E131&#x2013;E4. doi: 10.1002/ajh.25774</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.25774</ArticleId><ArticleId IdType="pubmed">32129508</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Zhang C, Huang F, Yang Y, Wang F, Yuan J, et al. . Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury. Natl Sci Rev (2020) 7(6):1003&#x2013;11. doi: 10.1093/nsr/nwaa037</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nsr/nwaa037</ArticleId><ArticleId IdType="pmc">PMC7107806</ArticleId><ArticleId IdType="pubmed">34676126</ArticleId></ArticleIdList></Reference><Reference><Citation>Adam L, Rosenbaum P, Quentric P, Parizot C, Bonduelle O, Guillou N, et al. . CD8+PD-L1+CXCR3+ polyfunctional T cell abundances are associated with survival in critical SARS-CoV-2-infected patients. JCI Insight (2021) 6(18): e151571. doi: 10.1172/jci.insight.151571</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.151571</ArticleId><ArticleId IdType="pmc">PMC8492305</ArticleId><ArticleId IdType="pubmed">34283810</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh Y, Trautwein C, Fendel R, Krickeberg N, Berezhnoy G, Bissinger R, et al. . SARS-CoV-2 infection paralyzes cytotoxic and metabolic functions of the immune cells. Heliyon (2021) 7(6):e07147. doi: 10.1016/j.heliyon.2021.e07147</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2021.e07147</ArticleId><ArticleId IdType="pmc">PMC8159709</ArticleId><ArticleId IdType="pubmed">34075347</ArticleId></ArticleIdList></Reference><Reference><Citation>Vigon L, Fuertes D, Garcia-Perez J, Torres M, Rodriguez-Mora S, Mateos E, et al. . Impaired cytotoxic response in PBMCs from patients with COVID-19 admitted to the ICU: Biomarkers to predict disease severity. Front Immunol (2021) 12:665329. doi: 10.3389/fimmu.2021.665329</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.665329</ArticleId><ArticleId IdType="pmc">PMC8187764</ArticleId><ArticleId IdType="pubmed">34122423</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Yu B, Yang Y, Huang J, Liang Y, Zhou J, et al. . Immunological and inflammatory profiles during acute and convalescent phases of severe/ critically ill COVID-19 patients. Int Immunopharmacol (2021) 97:107685. doi: 10.1016/j.intimp.2021.107685</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.107685</ArticleId><ArticleId IdType="pmc">PMC8052478</ArticleId><ArticleId IdType="pubmed">33951560</ArticleId></ArticleIdList></Reference><Reference><Citation>Tincati C, Cannizzo ES, Giacomelli M, Badolato R, d'Arminio Monforte A, Marchetti G. Heightened circulating interferon-inducible chemokines, and activated pro-cytolytic Th1-cell phenotype features covid-19 aggravation in the second week of illness. Front Immunol (2020) 11:580987. doi: 10.3389/fimmu.2020.580987</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.580987</ArticleId><ArticleId IdType="pmc">PMC7606391</ArticleId><ArticleId IdType="pubmed">33193384</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Wei X, Guan J, Qin S, Wang Z, Lu H, et al. . COVID-19 pneumonia: CD8(+) T and NK cells are decreased in number but compensatory increased in cytotoxic potential. Clin Immunol (2020) 218:108516. doi: 10.1016/j.clim.2020.108516</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108516</ArticleId><ArticleId IdType="pmc">PMC7305921</ArticleId><ArticleId IdType="pubmed">32574709</ArticleId></ArticleIdList></Reference><Reference><Citation>Riou C, Schafer G, du Bruyn E, Goliath RT, Stek C, Mou H, et al. . Rapid, simplified whole blood-based multiparameter assay to quantify and phenotype SARS-CoV-2-specific T-cells. Eur Respir J (2022) 59(1): 2100285. doi: 10.1183/13993003.00285-2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00285-2021</ArticleId><ArticleId IdType="pmc">PMC8215505</ArticleId><ArticleId IdType="pubmed">34140294</ArticleId></ArticleIdList></Reference><Reference><Citation>Law JC, Koh WH, Budylowski P, Lin J, Yue F, Abe KT, et al. . Systematic examination of antigen-specific recall T cell responses to SARS-CoV-2 versus influenza virus reveals a distinct inflammatory profile. J Immunol (2021) 206(1):37&#x2013;50. doi: 10.4049/jimmunol.2001067</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2001067</ArticleId><ArticleId IdType="pmc">PMC7750861</ArticleId><ArticleId IdType="pubmed">33208459</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsuyama Y, Yamakawa K, Kayano K, Maruyama M, Wada T, Fujimi S. Prolonged enhancement of cytotoxic T lymphocytes in the post-recovery state of severe COVID-19. J Intensive Care (2021) 9(1):76. doi: 10.1186/s40560-021-00591-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40560-021-00591-3</ArticleId><ArticleId IdType="pmc">PMC8685802</ArticleId><ArticleId IdType="pubmed">34930468</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko N, Boucau J, Kuo HH, Perugino C, Mahajan VS, Farmer JR, et al. . Temporal changes in T cell subsets and expansion of cytotoxic CD4+ T cells in the lungs in severe COVID-19. Clin Immunol (2022) 237:108991. doi: 10.1016/j.clim.2022.108991</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2022.108991</ArticleId><ArticleId IdType="pmc">PMC8961941</ArticleId><ArticleId IdType="pubmed">35364330</ArticleId></ArticleIdList></Reference><Reference><Citation>Melton A, Doyle-Meyers LA, Blair RV, Midkiff C, Melton HJ, Russell-Lodrigue K, et al. . The pigtail macaque (Macaca nemestrina) model of COVID-19 reproduces diverse clinical outcomes and reveals new and complex signatures of disease. PloS Pathog (2021) 17(12):e1010162. doi: 10.1371/journal.ppat.1010162</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010162</ArticleId><ArticleId IdType="pmc">PMC8722729</ArticleId><ArticleId IdType="pubmed">34929014</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore TC, Vogel AJ, Petro TM, Brown DM. IRF3 deficiency impacts granzyme b expression and maintenance of memory T cell function in response to viral infection. Microbes Infect (2015) 17(6):426&#x2013;39. doi: 10.1016/j.micinf.2015.03.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2015.03.001</ArticleId><ArticleId IdType="pmc">PMC4479197</ArticleId><ArticleId IdType="pubmed">25777301</ArticleId></ArticleIdList></Reference><Reference><Citation>Workman AM, Jacobs AK, Vogel AJ, Condon S, Brown DM. Inflammation enhances IL-2 driven differentiation of cytolytic CD4 T cells. PloS One (2014) 9(2):e89010. doi: 10.1371/journal.pone.0089010</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0089010</ArticleId><ArticleId IdType="pmc">PMC3930678</ArticleId><ArticleId IdType="pubmed">24586481</ArticleId></ArticleIdList></Reference><Reference><Citation>Laforge M, Silvestre R, Rodrigues V, Garibal J, Campillo-Gimenez L, Mouhamad S, et al. . The anti-caspase inhibitor q-VD-OPH prevents AIDS disease progression in SIV-infected rhesus macaques. J Clin Invest. (2018) 128(4):1627&#x2013;40. doi: 10.1172/JCI95127</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI95127</ArticleId><ArticleId IdType="pmc">PMC5873886</ArticleId><ArticleId IdType="pubmed">29553486</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasth AE, Snir O, Johansson AA, Nordmark B, Rahbar A, Af Klint E, et al. . Skewed distribution of proinflammatory CD4+CD28null T cells in rheumatoid arthritis. Arthritis Res Ther (2007) 9(5):R87. doi: 10.1186/ar2286</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar2286</ArticleId><ArticleId IdType="pmc">PMC2212553</ArticleId><ArticleId IdType="pubmed">17825098</ArticleId></ArticleIdList></Reference><Reference><Citation>Duftner C, Goldberger C, Falkenbach A, Wurzner R, Falkensammer B, Pfeiffer KP, et al. . Prevalence, clinical relevance and characterization of circulating cytotoxic CD4+CD28- T cells in ankylosing spondylitis. Arthritis Res Ther (2003) 5(5):R292&#x2013;300. doi: 10.1186/ar793</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar793</ArticleId><ArticleId IdType="pmc">PMC193730</ArticleId><ArticleId IdType="pubmed">12932293</ArticleId></ArticleIdList></Reference><Reference><Citation>Peeters LM, Vanheusden M, Somers V, Van Wijmeersch B, Stinissen P, Broux B, et al. . Cytotoxic CD4+ T cells drive multiple sclerosis progression. Front Immunol (2017) 8:1160. doi: 10.3389/fimmu.2017.01160</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01160</ArticleId><ArticleId IdType="pmc">PMC5611397</ArticleId><ArticleId IdType="pubmed">28979263</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Che N, Lu C, Sun X, Wang Y, Wang Q, et al. . Correlation of peripheral CD4+GranzB+CTLs with disease severity in patients with primary sjogren's syndrome. Arthritis Res Ther (2021) 23(1):257. doi: 10.1186/s13075-021-02632-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-021-02632-6</ArticleId><ArticleId IdType="pmc">PMC8507116</ArticleId><ArticleId IdType="pubmed">34641948</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. . COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (2020) 395(10229):1033&#x2013;4. doi: 10.1016/S0140-6736(20)30628-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30628-0</ArticleId><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Prilutskiy A, Kritselis M, Shevtsov A, Yambayev I, Vadlamudi C, Zhao Q, et al. . SARS-CoV-2 infection-associated hemophagocytic lymphohistiocytosis. Am J Clin Pathol (2020) 154(4): 466&#x2013;74. doi: 10.1101/2020.05.07.20094888</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.05.07.20094888</ArticleId><ArticleId IdType="pmc">PMC7454285</ArticleId><ArticleId IdType="pubmed">32681166</ArticleId></ArticleIdList></Reference><Reference><Citation>Sad S, Kagi D, Mosmann TR. Perforin and fas killing by CD8+ T cells limits their cytokine synthesis and proliferation. J Exp Med (1996) 184(4):1543&#x2013;7. doi: 10.1084/jem.184.4.1543</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.184.4.1543</ArticleId><ArticleId IdType="pmc">PMC2192809</ArticleId><ArticleId IdType="pubmed">8879227</ArticleId></ArticleIdList></Reference><Reference><Citation>Crouse J, Bedenikovic G, Wiesel M, Ibberson M, Xenarios I, Von Laer D, et al. . Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1. Immunity (2014) 40(6):961&#x2013;73. doi: 10.1016/j.immuni.2014.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2014.05.003</ArticleId><ArticleId IdType="pubmed">24909889</ArticleId></ArticleIdList></Reference><Reference><Citation>Madera S, Rapp M, Firth MA, Beilke JN, Lanier LL, Sun JC. Type I IFN promotes NK cell expansion during viral infection by protecting NK cells against fratricide. J Exp Med (2016) 213(2):225&#x2013;33. doi: 10.1084/jem.20150712</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20150712</ArticleId><ArticleId IdType="pmc">PMC4749923</ArticleId><ArticleId IdType="pubmed">26755706</ArticleId></ArticleIdList></Reference><Reference><Citation>Voskoboinik I, Whisstock JC, Trapani JA. Perforin and granzymes: function, dysfunction and human pathology. Nat Rev Immunol (2015) 15(6):388&#x2013;400. doi: 10.1038/nri3839</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3839</ArticleId><ArticleId IdType="pubmed">25998963</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene AL, Makrigiannis AP, Fitzpatrick L, Hoskin DW. Anti-CD3-activated killer T cells: Interleukin-6 modulates the induction of major histocompatibility complex-unrestricted cytotoxicity and the expression of genes coding for cytotoxic effector molecules. J Interferon Cytokine Res (1997) 17(12):727&#x2013;37. doi: 10.1089/jir.1997.17.727</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.1997.17.727</ArticleId><ArticleId IdType="pubmed">9452360</ArticleId></ArticleIdList></Reference><Reference><Citation>Smyth MJ, Ortaldo JR, Bere W, Yagita H, Okumura K, Young HA. IL-2 and IL-6 synergize to augment the pore-forming protein gene expression and cytotoxic potential of human peripheral blood T cells. J Immunol (1990) 145(4):1159&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">2143209</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deitchman AN, Torres L, Iyer NS, Munter SE, Nixon CC, et al. . Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep (2021) 36(6):109518. doi: 10.1016/j.celrep.2021.109518</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109518</ArticleId><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>